Dual modulation of MCL-1 and mTOR determines the response to sunitinib

Most patients who initially respond to treatment with the multi–tyrosine kinase inhibitor sunitinib eventually relapse. Therefore, developing a deeper understanding of the contribution of sunitinib’s numerous targets to the clinical response or to resistance is crucial. Here, we have shown that canc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Elgendy, Mohamed, Abdel-Aziz, Amal Kamal, Renne, Salvatore Lorenzo, Bornaghi, Viviana, Procopio, Giuseppe, Colecchia, Maurizio, Kanesvaran, Ravindran, Toh, Chee Keong, Bossi, Daniela, Pallavicini, Isabella, Perez-Gracia, Jose Luis, Lozano, Maria Dolores, Giandomenico, Valeria, Mercurio, Ciro, Lanfrancone, Luisa, Fazio, Nicola, Nole, Franco, Teh, Bin Tean, Renne, Giuseppe, Minucci, Saverio
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5199697/
https://ncbi.nlm.nih.gov/pubmed/27893461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI84386
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados